Filing Overview
Company: Cullinan Oncology, Inc. (now identified in the request metadata as Cullinan Therapeutics, Inc.)
Filing: Form 8-K filed June 4, 2021, reporting Regulation FD disclosure and other events. The filing furnished a press release and the company’s 2021 ASCO Annual Meeting presentation.
Business Context and Reporting Period
The disclosure concerns CLN-081, an orally available, irreversible EGFR inhibitor being evaluated in an ongoing Phase 1/2a trial for non-small cell lung cancer patients with EGFR exon 20 insertion mutations. The interim analysis used an April 1, 2021 data cutoff.
Clinical and Other Key Metrics
- Safety population: 45 patients had received at least one dose and were evaluable for safety across 30, 45, 65, 100, and 150 mg twice-daily dose levels.
- Response-evaluable population: 42 patients.
- Overall efficacy: Partial responses occurred in 21 of 42 patients, or 50%; 13 responses were confirmed, representing a 31% confirmed objective response rate.
- Five responses were pending confirmation and three were expected to remain unconfirmed.
- Forty-one of 42 response-evaluable patients, or 98%, achieved stable disease or a partial response; 76% showed some tumor regression at the initial post-baseline scan at week six.
- Safety: Rash occurred in 76% of patients across dose levels and was limited to Grade 1 or 2 events. No Grade 3 or higher treatment-related rash was reported.
- Diarrhea occurred in 22% of patients across dose levels; one Grade 3 or higher treatment-related event occurred at 150 mg twice daily and resolved with supportive care.
100 mg Twice-Daily Expansion Cohort
- The Phase 2a expansion cohort was designed to enroll up to 36 patients.
- Among 13 response-evaluable patients, seven, or 54%, had objective responses; six, or 46%, were confirmed.
- Nine of 13 patients, or 69%, achieved disease control, defined as a partial response of any duration or stable disease lasting at least six months. Three additional patients had stable disease, remained on treatment, and had been treated for less than six months at the data cutoff.
- Rash occurred in 66% of patients and was limited to Grade 1 or 2 events. Diarrhea occurred in 26%, with no Grade 3 or higher events reported in this cohort.
Financial Position and Capital Resources
This Form 8-K does not provide revenue, profit or loss, cash flow, cash balance, margins, debt, liquidity, or other financial statement metrics. The filing text does not provide a clear value for these items.
Management Commentary, Outlook, and Risks
The company characterized the interim results as supporting the clinical activity and tolerability of CLN-081, while noting that the trial remains ongoing and that some responses had not yet been confirmed. The filing does not provide specific financial guidance or a commercialization timetable.
Forward-looking statements relate to clinical development plans, trial designs, regulatory submissions, and the potential safety and activity of CLN-081. Identified risks include clinical-trial failure or unfavorable future results, regulatory delays, manufacturing and supply limitations, intellectual-property risks, COVID-19 impacts, unsuccessful development or commercialization of product candidates, and risks relating to collaborations or licensing arrangements.
The disclosure was furnished under Item 7.01 and was not deemed filed for purposes of Section 18 liability, except as expressly provided in a subsequent filing.
Investor Verification Items
- Verify subsequent data confirming or revising the reported partial responses and objective response rate.
- Review later clinical results for durability of response, progression-free survival, overall survival, and dose selection.
- Assess the completeness and maturity of the 100 mg twice-daily expansion cohort.
- Review later filings for cash resources, operating expenses, financing activity, and expected clinical-development runway.
- Evaluate regulatory, manufacturing, intellectual-property, collaboration, and COVID-19 risks described in subsequent SEC filings.